Terms: = Lung cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Treatment
22184 results:
1. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of a model for predicting upstage in minimally invasive lung adenocarcinoma in Chinese people.
Liao Y; Li Z; Song L; Xue Y; Chen X; Feng G
World J Surg Oncol; 2024 May; 22(1):135. PubMed ID: 38778366
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of Radiation Induced Pneumonitis and Pericarditis in Patients Undergoing Breast Conservative treatment Using Hypofractionated Simultaneous Integrated Boost Technique.
Sundaramoorthy S; Karunanidhi G; Pal P; C SV; Radhakrishnan H
Gulf J Oncolog; 2024 May; 1(45):15-29. PubMed ID: 38774929
[TBL] [Abstract] [Full Text] [Related]
4. The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer.
Ma H; Wu T; Zhang Q; Ding Q
BMC Pulm Med; 2024 May; 24(1):250. PubMed ID: 38773432
[TBL] [Abstract] [Full Text] [Related]
5. Interventions for smoking cessation in hospitalised patients.
Streck JM; Rigotti NA; Livingstone-Banks J; Tindle HA; Clair C; Munafò MR; Sterling-Maisel C; Hartmann-Boyce J
Cochrane Database Syst Rev; 2024 May; 5(5):CD001837. PubMed ID: 38770804
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical Multi-features Analysis of Cystic lung Adenocarcinoma
and Construction of Invasive Risk Prediction Model].
Wang Q; Fu C; Wang K; Ren Q; Chen A; Xu X; Chen L; Zhu Q
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):266-275. PubMed ID: 38769829
[TBL] [Abstract] [Full Text] [Related]
7. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
9. Clinic information, pathological, and imaging characteristics in 2 058 surgical patients with lung cancer from a single center.
Long B; Xiong Z; Liu S; Cheng Y; Li M; Liao W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):247-255. PubMed ID: 38755720
[TBL] [Abstract] [Full Text] [Related]
10. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
11. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of sex inequity in lung-cancer-specific survival.
Lærum D; Strand TE; Brustugun OT; Gallefoss F; Falk R; Durheim MT; Fjellbirkeland L
Acta Oncol; 2024 May; 63():343-350. PubMed ID: 38751329
[TBL] [Abstract] [Full Text] [Related]
13. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
14. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
15. Perioperative Nivolumab in Resectable lung cancer.
Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
[TBL] [Abstract] [Full Text] [Related]
16. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
17. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
Liang X; Xiao H; Li H; Chen X; Li Y
Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
[TBL] [Abstract] [Full Text] [Related]
18. Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.
Scotté F; Artru P; Saghatchian M; Chouaid C
Support Care Cancer; 2024 May; 32(6):347. PubMed ID: 38743147
[TBL] [Abstract] [Full Text] [Related]
19. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
20. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
[Next]
